SPRC SciSparc
- 1.2900
- -0.0300-2.27%
- 1.3100
- +0.0200+1.55%
SciSparc News
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
SciSparc To Acquire AutoMax, A Strategic Leap Towards Industry Diversification
Specialty clinical-stage pharmaceutical company SciSparc Ltd. (NASDAQ:SPRC) has entered into a merger agreement with AutoMax Motors Ltd., a vehicle importer company in Israel. Deal terms not disclosed.
Express News | SciSparc Shares Are Trading Higher. The Company Announced the Acquisition of AutoMax
Express News | SciSparc To Acquire AutoMax, Terms Not Disclosed
Express News | Scisparc Ltd - All Outstanding Shares of Automax Will Be Converted Into Right to Receive Ordinary Shares of Scisparc
Express News | Scisparc Ltd - Following Acquisition Scisparc Shareholders Will Hold Together About 50.01% of Share Capital of Post-Closing Combined Company
Express News | Scisparc Ltd - Will Acquire 100% of Automax and Establish a New Wholly-Owned Israeli Subsidiary
Press Release: SciSparc to Acquire AutoMax
SciSparc to Acquire AutoMax TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on
SciSparc To Acquire AutoMax >SPRC
SciSparc To Acquire AutoMax >SPRC
Express News | Scisparc to Acquire Automax
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Rallybio Corporation (NASDAQ:RLYB) rose sharply in today's pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individ
Express News | SciSparc Granted Canadian Patent #2984088 Titled "COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES (FOR TREATMENT OF CONDITIONS SUCH AS MOVEMENT DISORDERS, BODY-WEIGHT GAIN, CONFUSION, DISORIENTATION, ANXIETY, AND PREVENTION OF PAIN)"
SciSparc- Clearmind Collaboration Evolves With New International Patent Application for Preventing and Treating Depression
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to
Express News | SciSparc Shares Are Trading Higher After the Company's MitoCareX Joint Venture Said It Identified Molecules That Could Be Used for Potential Anti-cancer Treatments
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer...
TLRY, ACB and CGC Are Among Pre Market Gainers
SciSparc Granted Another Patent, Strengthening Its Core Technology in Canada
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders
SciSparc Achieves Major Milestone With First Patient Dosed in Autism Spectrum Disorder Clinical Trial
First patient has been dosed in the randomized, controlled, double blind clinical trial for Autism Spectrum Disorder in pediatric patients
SciSparc: MitoCareX Reveals Promising Results With Discovery of Novel Anti-Cancer Small Molecule Structure
Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments
SciSparc Ltd. (NASDAQ:SPRC) announced on Friday that it has enrolled the first patient in the company's clinical trial assessing the efficacy and safety of its cannabidiol (CBD) – based drug for the t
Analysis
Price Target
No Data
